Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
i don't have PM but I am glad you enjoyed that....lol
Uh....isn't that what your supposed to do... Sell higher than you bought...trading 101...WOW!!!!!!
Agreed that is huge volume and accumulation is through the roof. All the ingredients of going much higher. See ya tomorrow bud.
i remember watching that one. eerily similar. oh well i know ill make a bundle here. we will see how many other patient traders are on board with us.
Works like all the other big runners from low trips to 002-004 then reset back low 001's then rip off to 005-006 then reset to low .003's then rip to .01. see it all the time. It just takes a little time
For all the naysayers out there.....Why all the continued volume since initial breakout from .0001? i'll tell you why. MASSIVE CONTINUED INTEREST.......We go up in a big way shortly.
Strong possibility....but XTRN shares continue to trade freely and will still run hard. Hopefully the last round of exits
Don't think so but thanks.
it took me a long time to learn that. can't tell you how many i panic sold on. doesn't happen to me anymore. gl and hold tight, it's coming
Agreed besides it's so obvious what's going on here. This is one of those tickers that you see at .01 and say wish i was in that one....well we are. You know how I know that. Every single pump and dump is done in 2 days 1 huge green candle up then next day huge red candle down. Very rarely 3 days. I have been in 2 tickers in the past that this is behaving like and both made me a lot of money. You just have to be willing to sit through the tough days like today. I know what I own. Shorty is going to have to cover at some point:)
I have done that in the past and have learned. I am not missing this one. We are still copper bound. Can't be green every day. Tomorrow will be better
XTRN 20 mil buyout news last week. Billions in volume over 3 days. set up to run huge this week
would love to close 18 but not sure many traders left here end of day
XTRN anyone thinking rally into the close or has everyone already gone for the weekend???
XTRN time is getting short and 17's and 18's getting thin. Better get what u can now
XTRN. I keep wondering how on a Friday before a holiday weekend we are up over 13 percent. Last chance to get cheapskate. Going ballistic next week.
XTRN rut roh .0015 disappearing glad I got shares early
Tic tic to tic reversal coming for the day up up up. XTRN
Lol is that it. Selling done in 20 minutes. Ok so I guess 13's will suffice. Up from here all day
True we are still trading outside the upper bollie band. As it continues the rise so will the sp
CBIS MONSTER GOVT CONTRACT NEWS... maybe a trade here today
Cannabis Science, Inc. Receives U.S. Federal Government Clearance to Receive U.S. Federal Government Contracts
5/26/17, 8:17 AM
May 26, 2017 08:16 AM ET (BZ Newswire) -- Press Releases
Cannabis Science, Inc. Receives U.S. Federal Government Clearance to Receive U.S. Federal Government Contracts
Cannabis Science, Inc. Receives U.S. Federal Government Clearance to Receive U.S. Federal Government Contracts
IRVINE, CA--(Marketwired - May 26, 2017) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, has received U.S. Federal Government clearance to receive U.S. Federal Government contracts. As the world's largest customer, the U.S. Federal Government issues over $192 billion in contracts and over $450 billion in grants annually.
Cannabis Science has completed its registration in the U.S. Government's System for Award Management (SAM), and has applied for and received a Commercial and Government Entity (CAGE) Code from the Defense Logistics Agency's CAGE Program Office at the U.S. Department of Defense. Cannabis Science is now listed with all U.S. companies eligible for Federal Government Contracts. "Achieving eligibility to access contracting opportunities with the U.S. Federal Government is a significant step for Cannabis Science," stated Mr. Raymond C. Dabney, Cannabis Science's President, CEO, and Co-founder. "I believe we can leverage the unique experience and expertise of our company to win new business and grow Cannabis Science's revenue base. We also plan to work closely with our strategic partners and collaborators to access Federal contracting and grant opportunities."
Cannabis Science is registered in SAM with three North American Industry Classification System (NAICS) Codes:
541711 - Research and Development In Biotechnology
621511 - Medical Laboratories
624230 - Emergency and Other Relief Services
SAM is the primary vendor database for the U.S. Federal Government. Having vendor information immediately available allows the U.S. Government to rapidly find the companies with the right capabilities to offer services for required government contracts, government initiatives, research & development projects, and particular supply needs, as well as for pandemic alert and other emergency requirements.
Cannabis Science intends to explore funding opportunities, individually and with its collaborators, with institutions such as the National Institutes of Health (NIH), institutes within NIH, such as the National Institute on Drug Abuse (NIDA), and others.
As part of its mandate to study drug abuse and addiction and other health effects of both legal and illegal drugs, NIDA funds a wide range of research on marijuana (cannabis); its main psychotropic ingredient, delta-9-tetrahydrocannabinol (THC); and chemicals related to THC (cannabinoids). Research suggests that THC and other cannabinoids may have potential in the treatment of pain, nausea, epilepsy, obesity, wasting disease, addiction, autoimmune disorders, and other conditions. NIDA has provided and continues to provide funding for research related to therapeutic uses of cannabinoids as it pertains to its mission, including studies on the use of THC and cannabidiol (CBD), another chemical constituent of marijuana, for the treatment of pain (as an alternative to opioid pain relievers), addiction, and other disorders. Research on therapeutic uses of marijuana or of specific chemicals in the marijuana plant for other diseases and conditions is supported by other components of NIH as is appropriate to their mission. For a complete listing of all projects funded by NIH examining the potential therapeutic benefits of cannabinoids, see the Therapeutic Cannabinoid Research category in the NIH Report database.
The vast majority of research proposals received and funded by NIH on therapeutic benefits of cannabinoids have examined individual cannabinoid chemicals or, in a few cases, marijuana leaves delivered through some means other than smoking. Research proposals submitted to any NIH Institute of Center (IC) to study therapeutic benefits of marijuana or one of its ingredients must meet the same accepted standards of scientific design as any other proposal and, on the basis of peer review, should meet public health significance and IC priorities to be competitive with other applications that qualify for funding. NIDA is a scientific, not a policy-making agency. The same is true for the NIH as a whole. NIDA's role is to conduct and support scientific research on drugs and drug abuse and to advise the public and policy-makers, such as Congress, the White House Office of the National Drug Control Policy, and the U.S. Drug Enforcement Administration on the results of that research -- with the goal of ensuring that the nation's drug policies are informed by science. That said, NIDA does closely watch legislative changes both nationally and at the state level and supports research that studies how changing drug policies -- for instance laws around recreational or therapeutic use of marijuana -- affect rates of substance use and related public health issues.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
Cannabis Science, Inc.
Jacques P. Walker
Member, International Government Affairs Board
jacques.walker@cannabisscience.com
Tel: 1-888-263-0832
Cannabis Science, Inc.
Dr. Allen Herman
Chief Medical Officer (CMO)
allen.herman@cannabisscience.com
Tel: 1-888-263-0832
Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
raymond.dabney@cannabisscience.com
Tel: 1-888-263-0832
Copyright 2017 Benzinga (BZ Newswire, http://www.benzinga.com/licensing). Benzinga does not provide investmentadvice. All rights reserved.
Write to editorial@benzinga.com with any questions about this content. Subscribe to Benzinga Pro (http://pro.benzinga.com).
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Thx flex. When u go where the money is, it's pretty easy to do. Still have some freebies just in case this really goes parabolic
Hey Flex good to see you full bore today on the board. XTRN so strong and can't believe the volume there. Been an ATM for 3 days running. Happy trading
Marked trader although I do not have pm, I will be glad to receive them thanke
Lol yes.... thanks for keeping me on the strait and narrow
It does look really attractive. Will look into it more tonight as can't make a move until tomorrow anyways
Sometimes I feel like I need 60k to play me all..... lol
Ohhhh maybe I'll go here tomorrow. Too many for the liking.
Think I may be bidding for 4's there tomorrow. Caught in between trades and not clearing til the am
Looking foward flex. Let's make some trades today
30 mil added to bid from open today. Interest is coming
The game was awful for Syracuse. Towson had possession almost entire game. Nephew played pretty well. Have an awesome trading dY flex. I'm out til later
Enjoy the rest of the weekend. Big Syracuse LaCrosse game tomorrow. Nephew playing as freshman...Go Orange
That is hysterical
Any Thoughts on NSPR....looks way oversold appears to have reached bottom and was able to get in under the VWAP..lets see what happens
Looks like selling is drying up. Trying to get in on bid. Only small partial fill
Going to add 2.5 mil more as soon as Funds clear
We will see keeping another eye out there. Maybe another flex in it
SNVP just wait for the real run. 005 easy with this ss
Tee hee...we shall see.....adding here